Georgia Erbez - Jul 1, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Director
Signature
/s/ Georgia Erbez; By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/1/2022, 04:25 PM
Previous filing
Feb 1, 2022
Next filing
Feb 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -18K -100% $0.00* 0 Jul 1, 2022 Common Stock 18K $17.76 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Georgia Erbez is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.
F2 Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.